Clinical Trial Update: A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) [Phase 1, Phase 2]

View source ↗

Summary

Astellas-sponsored study evaluating intermittent and continuous OSI-906 with weekly paclitaxel in recurrent ovarian cancer and other solid tumors has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• OSI-906 (OSI-906)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Ovarian Cancer, Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED